Abstract
A rugged, sensitive and efficient liquid chromatography–tandem mass spectrometry method was developed and validated for the quantitative analysis of firocoxib in urine from 5 to 3000ng/mL and in plasma from 1 to 3000ng/mL. The method requires 200μL of either plasma or urine and includes sample preparation in 96-well solid phase extraction (SPE) plates using a BIOMEK® 2000 Laboratory Automated Workstation. Chromatographic separation of firocoxib from matrix interferences was achieved using isocratic reversed phase chromatography on a PHENOMENEX LUNA® Phenyl-Hexyl column. The mobile phase was 45% acetonitrile and 55% of a 2mM ammonium formate buffer. The method was accurate (88–107%) and precise (CV<12.2%) within and between sets. Extraction efficiencies (recovery) >93% were achieved and ionization efficiencies (due to matrix effects) were >72%. Extensive stability and ruggedness testing was also performed; therefore, the method can be used for pharmacokinetic studies as well as drug monitoring and screening. The data presented here is the first LC–MS/MS method for the quantitation of firocoxib in plasma (LLOQ of 1ng/mL), a 25-fold improvement in sensitivity over the HPLC-UV method and the first quantitative method for firocoxib in urine (LLOQ of 5ng/mL). Additionally the sample preparation process has been automated to improve efficiency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
